Tigecycline (Tygacil): A novel first-in-class, broad-spectrum intravenous antibiotic for the treatment of serious bacterial infections

P and T

Volumn 31, Issue 1, 2006, Pages

  Harris, Robert ^a   Cruz, Martin ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Hampton VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; AZTREONAM; CHLORPROMAZINE; CILASTATIN PLUS IMIPENEM; CYTOCHROME P450; DALFOPRISTIN PLUS QUINUPRISTIN; DOBUTAMINE; DOPAMINE; GENERIC DRUG; LIDOCAINE; LINEZOLID; METHYLPREDNISOLONE; PLACEBO; POTASSIUM CHLORIDE; RANITIDINE; RINGER LACTATE SOLUTION; THEOPHYLLINE; TIGECYCLINE; VANCOMYCIN; VORICONAZOLE; WARFARIN;

ABDOMINAL INFECTION; ABDOMINAL PAIN; ABSCESS; ANEMIA; ANOREXIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; APPENDICITIS; BACTERIAL INFECTION; BRADYCARDIA; COUGHING; DEATH; DIARRHEA; DIZZINESS; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DYSPEPSIA; FEVER; GASTROINTESTINAL TOXICITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEADACHE; HOSPITAL INFECTION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPOPROTEINEMIA; INJECTION SITE PAIN; JAUNDICE; LEUKOCYTOSIS; LIVER TOXICITY; NAUSEA; PANCREAS DISEASE; PERIPHERAL EDEMA; REVIEW; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; WOUND HEALING IMPAIRMENT; XEROSTOMIA;

EID: 31544465944     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Centers for Disease Control and Prevention. Available atwww.cdc.gov.
2. Tygacil (tigecycline) clinical monograph, prescribing information, Philadelphia, PA: Wyeth Pharmaceuticals, Inc.
3. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/ pharmacodynamic profile for tigecycline: A new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005;52: 165-171.
4. Masterton R, Drusano G, Paterson DL, et al. Appropriate antimicrobial treatment in nosocomial infections: The clinical challenges. J Hosp Infect 2003;55:1-12.
5. Stalam M, Kaye D. Antibiotic agents in the elderly. Infect Dis Clin North Am 2000;14:357-369.
6. FDA approves Tygacil, first-in-class antibiotic. Wyeth Pharmaceuticals. Available at: www.wyeth.com. Accessed August 29, 2005.
7. Livermore DM. Tigecycline: What is it, and where should it be used? J Antimicrob Chemother 2005;10:1-4.
8. Clinical pharmacology. Tygacil product monograph. Available at: www.cpip. gsm.com. Accessed September 2, 2005.
9. Sum PE, Petersen PJ. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg Med Chem Lett 1999;9:1459-1462.
10. Tygacil's mechanism of action. Available at: www.tygacil.com. Accessed September 21, 2005.
11. Bergeron J, Ammirati M, Danley D, et al. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother 1996;40:2226-2228.
12. 2+ cleavage of 16S rRNA. J Antimicrob Chemother 2004;53:592-599.
13. Bradford PA. Tigecycline: A first in class glycylcycline. Clin Microbiol Newsletter 2004;26:163-168.
14. Babinchak T, Ellis-Grosse E, Dartois N, et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data. Clin Infect Dis 2005;41:S354-S367.
15. Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005;41:S315-S332.
16. Sacchidanand S, Perm RL, Embil JM, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. J Infect Dis 2005;9:251-261.
17. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin structure infections: Results of two double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41:S341-S353.
18. Postier RG, Green SL, Klein SR, Ellis-Grosse EJ. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin structure infections in hospitalized patients. Clin Ther 2004;26:704-714.
19. Tygacil (tigecycline) Average wholesale price policy. Available at www.micromedex.com/products/redbook/awp.